BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Policy

  How to Transition From Academia to Government

  For those looking to transition out of academia, moving into a government role could be one of the most rewarding pathways available.

  April 25, 2023

   · 

  5 min read

   · 

  Eden Whitlock
• 

  Policy

  FDA Approves Biogen and Ionis’ Qalsody as Fourth-Ever ALS Therapy

  Tuesday, the FDA approved Qalsody—formerly tofersen—on a conditional basis to treat SOD1-ALS.

  April 25, 2023

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Applied Therapeutics Seeks NDA for Rare Pediatric Disease Drug Despite Phase III Failure

  Govorestat failed its primary composite measure but showed signals of efficacy, leading the company to push forward with an NDA.

  April 25, 2023

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Bluebird Submits BLA for Sickle-Cell Disease Gene Therapy

  The regulatory filing puts the company alongside Vertex and CRISPR, which also await FDA approval for their SCD gene therapy.

  April 25, 2023

   · 

  4 min read

   · 

  Ashley P. Taylor
• 

  Drug Development

  Vedanta Raises $106.5M to Advance New Class of C. diff Therapeutics

  Vedanta will use the funds to advance its lead asset VE303 in clostridioides difficile infection and support the development of another candidate in ulcerative colitis.

  April 25, 2023

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  FDA Presses Pause on Another Foghorn Program

  The partial clinical hold follows Foghorn’s voluntary pause of the study and is due to one patient developing irregular heartbeat following treatment with FHD-609.

  April 25, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• Drug Development

  OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease

  OKYO Pharma Limited announces the activation of the first clinical trial site in the U.S. for its phase 2, multi-center, randomized, double-blinded, placebo-controlled trial, evaluating the efficacy and safety of OK-101 ophthalmic solution in subjects with dry eye disease.

  April 25, 2023

   · 

  3 min read
• Neteera Secures ~$13M Series B Funding for Contactless Patient Monitoring

  Neteera Technologies Ltd., an Israeli-based startup disrupting the patient monitoring market, announced the successful closing of a ~$13M Series B funding round.

  April 25, 2023

   · 

  4 min read
• Business

  Danaher Reports First Quarter 2023 Results

  Danaher Corporation announced results for the first quarter 2023. Net earnings refer to net earnings attributable to common shareholders.

  April 25, 2023

   · 

  25 min read
• Business

  Centene Corporation Reports First Quarter 2023 Results

  Centene’s first quarter results were strong, reflective of continued positive momentum operationally and the beginning of another year of disciplined execution against our strategic framework.

  April 25, 2023

   · 

  28 min read